Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Operating Expenses (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Operating Expenses data on record, last reported at $43.5 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 0.56% year-over-year to $43.5 million; the TTM value through Dec 2025 reached $183.3 million, up 11.94%, while the annual FY2025 figure was $183.3 million, 11.94% up from the prior year.
  • Operating Expenses reached $43.5 million in Q4 2025 per TRDA's latest filing, down from $48.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $48.8 million in Q2 2025 and bottomed at $22.2 million in Q1 2022.
  • Average Operating Expenses over 4 years is $36.0 million, with a median of $37.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 46.17% in 2023, then increased 0.56% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $25.6 million in 2022, then skyrocketed by 44.43% to $36.9 million in 2023, then increased by 17.11% to $43.3 million in 2024, then grew by 0.56% to $43.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $43.5 million in Q4 2025, $48.7 million in Q3 2025, and $48.8 million in Q2 2025.